— CorMedix Inc. (NYSE: CRMD) reported a fourth-quarter 2019 loss of $0.21 per share versus a loss of $0.24 per share expected.
— The latest quarter’s loss was compared to the prior-year quarter’s profit of $0.10 per share. This was due to the reversal of clinical trial expenses as a result of the settlement agreement with its CRO in 2018.
— Net sales fell by 7% year-over-year to $25 thousand versus $90 thousand expected.
— The company has begun the submission process of the New Drug Application (NDA) for Neutrolin for the prevention of catheter-related bloodstream infections in hemodialysis patients.
— The company believes it is on schedule for potential approval of the NDA for use in adult hemodialysis patients during the second half of 2020.
— CorMedix has been approved to transfer about $5.5 million of the total $6 million of its available tax benefits to an unrelated, profitable New Jersey corporation for about $5.2 million in net proceeds.
— Total cash on hand and short-term investments as of December 31, 2019, amounted to $28.3 million, excluding restricted cash of $0.2 million.
— The company believes it has sufficient resources to fund operations into the second quarter of 2021, including the submission of the NDA for Neutrolin and initial preparations for commercial launch.
The market crash triggered by the covid-19 outbreak has added to the troubles of Alcoa Corporation (NYSE: AA), which is already facing multiple challenges including falling aluminum prices, slowing economic
BlackBerry Limited (NYSE: BB) is slated to report its fourth-quarter 2020 earnings results on Tuesday, March 31, after the market closes. The top line will be benefited by BlackBerry Cylance
The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone. As the world grapples with the outbreak, several